Quality of life: substantial improvement · schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · schizophrenia
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson… compared with ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Adverse effects: 3. Metabolic weight gain ≥7% of total body weight · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain ≥7% of total body weight compared with ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Intervention not reported
ABC ‐ Irritability subscale Mean score changes 8 weeks of treatment · children/youth with ASD
1 finding from 1 review
Intervention not reported
ABC ‐ Hyperactivity subscale Mean score changes 8 weeks of treatment · children/youth with ASD
1 finding from 1 review
Intervention not reported
ABC ‐ Stereotypy subscale Mean score changes 8 weeks of treatment · children/youth with ASD
1 finding from 1 review
Intervention not reported
Weight gain 8 weeks of treatment · children/youth with ASD
1 finding from 1 review
Intervention not reported
Sedation 8 weeks of treatment · children/youth with ASD
1 finding from 1 review
Intervention not reported
Tremor 8 weeks of treatment · children/youth with ASD
1 finding from 1 review
Intervention not reported
Relapse rate 16 weeks of treatment · children/youth with ASD
1 finding from 1 review
Intervention not reported
Poor compliance with study protocol · people with schizophrenia or like psychosis
The intervention may leads to lower poor compliance with study protocol (low certainty).
1 finding from 1 review
Intervention not reported
Relapse · people with schizophrenia or like psychosis
The intervention may leads to lower relapse (low certainty).
1 finding from 1 review
Intervention not reported
Weight gain (equal or greater then 7% of baseline) · people with schizophrenia or like psychosis
The intervention may leads to higher weight gain (equal or greater then 7% of baseline) (low certainty).
1 finding from 1 review
Intervention not reported
Concomitant medication (Anxiolytic ‐ Lorazepam) · people with schizophrenia or like psychosis
The intervention may leads to lower concomitant medication (Anxiolytic ‐ Lorazepam) (low certainty).
1 finding from 1 review